Tools & Diagnostics
Digital Health
Tech-Enabled Services
Leaders in Healthcare Technology Investing
See All"We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”
Jan 08, 2024
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023, beginning 2024 with cash balance of $66.5 million.
Announced completion of patient implant milestone in the NAUTILUS trial.
Completed initial milestones in first strategic data collaboration, using proprietary biomarker monitoring and data analysis capabilities to support a clinical-stage biotechnology company’s clinical trial.
Pilot Launch of Project CARE program to advance RNS System access to community setting expected in 1H 2024.
Dec 21, 2023
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal StudyNAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy. Neuromodulation therapy is not currently indicated for patients with drug refractory generalized epilepsy. If successful, NeuroPace’s RNS System would represent the first neuromodulation indication in idiopathic generalized epilepsy
Dec 05, 2023
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking CollaborationFirst of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial. In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to $3.7 million over two years to gain non-exclusive access to NeuroPace’s proprietary biomarker monitoring and data analysis capabilities for trial patients
Nov 28, 2023
Keystone Dental Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateQ3 revenue increased 18.9% year-over-year to $16.8M, including $11.9M from the U.S.
Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Meeting on Monday, December 18th, 2023